Woburn, MA (February 14, 2005) – U.S. Genomics announced today its sponsorship of the Biophysical Society Outstanding Investigator Award in the Field of Single Molecule Biology. The sponsorship announcement coincides with the Biophysical Society 49th Annual Meeting, held this week in Long Beach, California. The Biophysical Society Awards Program honors its members by recognizing excellence in biophysics and promoting greater interaction among life scientists throughout the world.

“The Biophysical Society Annual Meeting is the premier event to acknowledge great achievements in single molecule biology,” said Stephen P. DeFalco, Chairman and CEO of U.S. Genomics. “As the pioneer of single molecule biology tools, U.S. Genomics is excited to establish the first award to recognize and promote outstanding contributions in this field.”

“The Biophysical Society unanimously and enthusiastically supports the establishment of U.S. Genomics’ Outstanding Investigator Award in the Field of Single Molecule Biology,“ said Stephen Harvey, President of the Biophysical Society. “This award will encourage future exploration and acknowledge excellence in this advanced area of biophysics research.”

Descriptions of the award and criteria for nominations will be posted at www.biophysics.org. The first recipient of the Outstanding Investigator Award in the Field of Single Molecule Biology will be honored at the Biophysical Society’s 50th Annual Meeting to be held February 18-22, 2006 in Salt Lake City, Utah.


About U.S. Genomics, Inc.
U.S. Genomics is pioneering single molecule biology tools for the global life sciences industry. The company provides instruments and reagents for researchers in academia, contract service organizations, pharmaceutical and biotech companies, as well as healthcare providers. Combining advances in microfluidics, optical engineering, and novel labeling strategies, U.S. Genomics’ innovative technologies allow genetics, functional genomics, biodefense, and diagnostics to be performed at the single molecule level. The Trilogy™ platform is the first commercially available technology to enable the direct detection and analysis of individual molecules of DNA, RNA, and proteins without the need for amplification. In addition, the company is developing the next generation of biodetection technology for the U.S. Department of Homeland Security. U.S. Genomics’ portfolio of products will further a greater understanding of human genetics and disease pathways, and ultimately lead to more effective therapeutics and diagnostics. For more information, please visit www.usgenomics.com.

About the Biophysical Society
The Biophysical Society, founded in 1956, is a professional, scientific society established to encourage development and dissemination of knowledge in biophysics. The Society promotes growth in this expanding field through its annual meeting, monthly journal, and committee and outreach activities. Its members are located in the U.S. and around the world, where they teach and conduct research in colleges, universities, laboratories, government agencies, and industry.


Trilogy and U.S. Genomics are trademarks of U.S. Genomics, Inc.